Limits...
Antitumor and antimetastatic activities of chloroform extract of medicinal mushroom Cordyceps taii in mouse models.

Liu RM, Zhang XJ, Liang GY, Yang YF, Zhong JJ, Xiao JH - BMC Complement Altern Med (2015)

Bottom Line: Furthermore, CFCT at a dose of 50 or 100 mg/kg could significantly inhibit the tumor growth in vivo and prolonged the survival time in two different models as compared with the model group, especially when combined with the CTX at a low dose rate.The antimetastatic effect was also observed when CFCT was used in combination with CTX.In comparison to any other groups, CFCT at a dose of 100 mg/kg could effectively enhance the GSH-Px activities of various tissues in tumor-bearing C57BL/6 mice.

View Article: PubMed Central - PubMed

Affiliation: Guizhou Center for Translational Medicine & Laboratory of Cell Engineering, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China. lrm407@126.com.

ABSTRACT

Background: Cordyceps taii, an entomogenous fungus native to south China, is a folk medicine with varieties of pharmacological activities including anticancer effect. To validate the ethnopharmacological claim against cancer, the antitumor and antimetastatic activities of chloroform extract of C. taii (CFCT) were investigated in vivo.

Methods: The in vitro cytotoxic activities of CFCT against human lung cancer (A549) and gastric cancer (SGC-7901) cells were evaluated using the Sulforhodamine B (SRB) assay. In vivo anti tumor and antimetastatic activities, Kunming mice bearing sarcoma 180 and C57BL/6 mice bearing melanoma B16F10 were employed, respectively. The antitumor effects of CFCT were completely evaluated on the basis of the tumor weight, survival time, histologic analysis, and immune organ indices. The histopathological change, metastatic foci and malignant melanoma specific marker HMB45 in the lung tissue were detected for the evaluation of the antimetastatic activity of CFCT.

Results: CFCT exhibited dose- and time-dependent cytotoxicities against A549 and SGC-7901 cells with the IC50 values of 30.2 and 65.7 μg/mL, respectively. Furthermore, CFCT at a dose of 50 or 100 mg/kg could significantly inhibit the tumor growth in vivo and prolonged the survival time in two different models as compared with the model group, especially when combined with the CTX at a low dose rate. And it also increased spleen index of Kunming mice and thymus index of C57BL/6 mice. Meanwhile, histologic analysis illustrated that CFCT alone or in combination with CTX could induce tumor tissue necrosis of both models. In addition, CFCT at a dose of 50 or 100 mg/kg inhibited the lung metastasis of melanoma B16F10 in tumor-bearing C57BL/6 mice. The antimetastatic effect was also observed when CFCT was used in combination with CTX. In comparison to any other groups, CFCT at a dose of 100 mg/kg could effectively enhance the GSH-Px activities of various tissues in tumor-bearing C57BL/6 mice.

Conclusions: These findings demonstrate that CFCT has potent in vivo antitumor and antimetastatic activities, and may be helpful to the development of anticancer chemopreventive agents from C. taii.

No MeSH data available.


Related in: MedlinePlus

Antitumor effect of CFCT in melanoma B16F10-bearing C57BL/6 mice. a Inhibitory rate in treatment groups. Values were expressed as mean ± SD (n = 8). The inhibitory ratio = (the average tumor weight of model group - the average tumor weight of treatment group)/the average tumor weight of model group × 100 %; b Representative HE staining sections from different groups. Blue arrows denote necrotic tissues. *P < 0.05, **P < 0.01 vs. model group. All groups as described with Fig. 2
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4495694&req=5

Fig3: Antitumor effect of CFCT in melanoma B16F10-bearing C57BL/6 mice. a Inhibitory rate in treatment groups. Values were expressed as mean ± SD (n = 8). The inhibitory ratio = (the average tumor weight of model group - the average tumor weight of treatment group)/the average tumor weight of model group × 100 %; b Representative HE staining sections from different groups. Blue arrows denote necrotic tissues. *P < 0.05, **P < 0.01 vs. model group. All groups as described with Fig. 2

Mentions: CFCT could inhibit the tumor growth of murine metastatic melanoma B16F10-bearing mice in comparison with the model group, especially in the HG and CG groups (Table 2). As shown in Fig. 3a, it resulted in more than 30 % inhibition in both HG group (P < 0.05) and CG group (P < 0.01) compared with the model group. However, no significant difference of tumor weight was observed between LG group and the model group. Further histopathological analysis of tumor tissue with HE staining displayed a large number of necrotic cancer cells or tissues (blue arrow denote necrotic cells) in the HG and CG groups (Fig. 3b). Therefore, these data suggested that CFCT could moderately inhibit tumor growth in B16F10-bearing C57BL/6 mice.Table 2


Antitumor and antimetastatic activities of chloroform extract of medicinal mushroom Cordyceps taii in mouse models.

Liu RM, Zhang XJ, Liang GY, Yang YF, Zhong JJ, Xiao JH - BMC Complement Altern Med (2015)

Antitumor effect of CFCT in melanoma B16F10-bearing C57BL/6 mice. a Inhibitory rate in treatment groups. Values were expressed as mean ± SD (n = 8). The inhibitory ratio = (the average tumor weight of model group - the average tumor weight of treatment group)/the average tumor weight of model group × 100 %; b Representative HE staining sections from different groups. Blue arrows denote necrotic tissues. *P < 0.05, **P < 0.01 vs. model group. All groups as described with Fig. 2
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4495694&req=5

Fig3: Antitumor effect of CFCT in melanoma B16F10-bearing C57BL/6 mice. a Inhibitory rate in treatment groups. Values were expressed as mean ± SD (n = 8). The inhibitory ratio = (the average tumor weight of model group - the average tumor weight of treatment group)/the average tumor weight of model group × 100 %; b Representative HE staining sections from different groups. Blue arrows denote necrotic tissues. *P < 0.05, **P < 0.01 vs. model group. All groups as described with Fig. 2
Mentions: CFCT could inhibit the tumor growth of murine metastatic melanoma B16F10-bearing mice in comparison with the model group, especially in the HG and CG groups (Table 2). As shown in Fig. 3a, it resulted in more than 30 % inhibition in both HG group (P < 0.05) and CG group (P < 0.01) compared with the model group. However, no significant difference of tumor weight was observed between LG group and the model group. Further histopathological analysis of tumor tissue with HE staining displayed a large number of necrotic cancer cells or tissues (blue arrow denote necrotic cells) in the HG and CG groups (Fig. 3b). Therefore, these data suggested that CFCT could moderately inhibit tumor growth in B16F10-bearing C57BL/6 mice.Table 2

Bottom Line: Furthermore, CFCT at a dose of 50 or 100 mg/kg could significantly inhibit the tumor growth in vivo and prolonged the survival time in two different models as compared with the model group, especially when combined with the CTX at a low dose rate.The antimetastatic effect was also observed when CFCT was used in combination with CTX.In comparison to any other groups, CFCT at a dose of 100 mg/kg could effectively enhance the GSH-Px activities of various tissues in tumor-bearing C57BL/6 mice.

View Article: PubMed Central - PubMed

Affiliation: Guizhou Center for Translational Medicine & Laboratory of Cell Engineering, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China. lrm407@126.com.

ABSTRACT

Background: Cordyceps taii, an entomogenous fungus native to south China, is a folk medicine with varieties of pharmacological activities including anticancer effect. To validate the ethnopharmacological claim against cancer, the antitumor and antimetastatic activities of chloroform extract of C. taii (CFCT) were investigated in vivo.

Methods: The in vitro cytotoxic activities of CFCT against human lung cancer (A549) and gastric cancer (SGC-7901) cells were evaluated using the Sulforhodamine B (SRB) assay. In vivo anti tumor and antimetastatic activities, Kunming mice bearing sarcoma 180 and C57BL/6 mice bearing melanoma B16F10 were employed, respectively. The antitumor effects of CFCT were completely evaluated on the basis of the tumor weight, survival time, histologic analysis, and immune organ indices. The histopathological change, metastatic foci and malignant melanoma specific marker HMB45 in the lung tissue were detected for the evaluation of the antimetastatic activity of CFCT.

Results: CFCT exhibited dose- and time-dependent cytotoxicities against A549 and SGC-7901 cells with the IC50 values of 30.2 and 65.7 μg/mL, respectively. Furthermore, CFCT at a dose of 50 or 100 mg/kg could significantly inhibit the tumor growth in vivo and prolonged the survival time in two different models as compared with the model group, especially when combined with the CTX at a low dose rate. And it also increased spleen index of Kunming mice and thymus index of C57BL/6 mice. Meanwhile, histologic analysis illustrated that CFCT alone or in combination with CTX could induce tumor tissue necrosis of both models. In addition, CFCT at a dose of 50 or 100 mg/kg inhibited the lung metastasis of melanoma B16F10 in tumor-bearing C57BL/6 mice. The antimetastatic effect was also observed when CFCT was used in combination with CTX. In comparison to any other groups, CFCT at a dose of 100 mg/kg could effectively enhance the GSH-Px activities of various tissues in tumor-bearing C57BL/6 mice.

Conclusions: These findings demonstrate that CFCT has potent in vivo antitumor and antimetastatic activities, and may be helpful to the development of anticancer chemopreventive agents from C. taii.

No MeSH data available.


Related in: MedlinePlus